Abstract: Prostate cancer is a heterogeneous disease with disparate outcomes. Traditional clinical parameters are limited in their ability to differentiate between these cases, and there is uncertainty regarding management strategies. A number of novel biomarkers have emerged, but how best to use them at the point of care remains confusing. In the present review, we describe the most common novel biomarkers, their key supporting literature, and propose a meaningful algorithm for their use in clinical practice. To identify commercially available prostate cancer diagnostic tests, we carried out a PubMed literature search (through May 2016). Only English-language studies were included. We restricted our search to studies published within the past 10 years in order to focus our review on novel data. Secondary sources were also examined. We identified 12 novel biomarkers and categorized them into broad areas of clinical practice: (i) early diagnosis and screening; (ii) staging and primary treatment selection; (iii) post-treatment risk stratification; (iv) advanced disease prognosis and treatment response; and (v) emerging tests. Most validation studies rely on small retrospective cohorts and carry a high risk of bias; furthermore, most cohorts are restricted to Caucasians, with little to no representation of other geographic, racial or ethnic populations. Novel biomarkers for prostate cancer management, while potentially helpful, should not replace standard clinical information and physician judgment. They are currently best suited to serve as an adjunct to existing management tools. Clinicians should have a sound grasp of each biomarker-based test's indications and limitations.
Introduction
Prostate cancer is the most common cancer diagnosis, and the second most common cause of cancer-related deaths among men in the USA. Despite this, prostate cancer is heterogeneous entity, with cancers ranging from indolent forms unlikely to impact a man's longevity, to lethal disease. Information such as PSA level, cancer stage, and Gleason score, are limited in their ability to determine disease severity, making many clinical decisions difficult. A number of new tools have emerged -including MRI and novel genomic and molecular biomarkersthat might help manage some of the clinical challenges associated with prostate cancer. These include when to carry out an initial or repeat biopsy, how to select patients for active surveillance, how to determine who might benefit from adjuvant or salvage local therapies, and how to determine prognosis and treatment responses for men with advanced disease. The rapid innovation in new biomarkers, however, has also raised questions of how to best use these tests at the point of care, and whether the additional information they provide justifies their costs.
In the present review, we describe the most common novel biomarkers, their key supporting literature, identify their limitations, and propose a meaningful algorithm for their use in clinical practice. "biomarker," and "prostate cancer genetic test." Only English-language studies were included. We restricted our analysis to studies published within the past 10 years. In addition, we examined secondary sources from reference lists of retrieved articles, data presented at recent congresses and reference lists provided by vendors.
We excluded biomarkers from our study that had only preclinical data, without any clinically relevant studies. We focused on clinical validation studies, defined as those that address the relationship between a test/biomarker and a predefined clinical outcome. 1 
Results
Approximately 1600 studies were identified on our initial search. After exclusions, we included 39 studies that discussed 12 novel biomarkers or genomic tests relevant to the management of prostate cancer (Table 1) . We categorized the tests into broad areas of clinical practice regarding prostate cancer: (i) early diagnosis and screening; (ii) staging and primary treatment selection; (iii) post-treatment risk stratification; (iv) advanced disease prognosis and treatment response; and (v) emerging tests that are still difficult to categorize.
Early diagnosis and screening
Tests in this category can be used to stratify men with an elevated PSA into those most likely to have a positive prostate biopsy or those with a greater likelihood of higher-risk disease. The goals of such tests are to improve the limited specificity and risk stratification of PSA, and to avoid the morbidity of an unnecessary biopsy.
4Kscore
The 4Kscore blood test (OPKO Laboratory, Nashville, TN, USA) predicts the likelihood that a patient will have highgrade cancer (defined as a Gleason score of ≥7) on a needle biopsy. It measures the levels of a panel of four kallikrein proteins, including total PSA, free PSA, intact (single-chain) PSA and human kallikrein 2. That information, along with DRE findings and any previous prostate biopsy results, is incorporated into an algorithm that is used to generate a probability score between 0% and 100%. This algorithm is primarily based on data from the European Randomized Study of Screening for Prostate Cancer.
In an early validation study, blood was obtained from 1012 biopsy na€ ıve men at 26 centers in the USA who were scheduled to undergo a biopsy. 2 Various 4Kscore cut-offs were evaluated to identify an appropriate threshold for detecting high-grade cancer. Among those with a positive biopsy, the 4Kscore accurately predicted the probability of high-grade cancer (AUC 0.821, 95% CI 0.790-0.852) with the potential to eliminate unnecessary biopsies. For example, a 4Kscore cut-off value of ≥9% was shown to avoid 434 (31.2%) of the scheduled biopsies. Another recent clinical utility study assessing the impact of the 4Kscore in practice found that its use was associated with a 64.6% reduction in prostate biopsies, whereas high-grade prostate cancer was found in 81% of the men who did proceed to a biopsy (Table S1) . 3 The primary utility of the 4Kscore is to find clinically significant prostate cancer and to minimize the number of unnecessary biopsies in previously undiagnosed patients. It is certified by the CLIA program of the Centers for Medicare and Medicaid Services, but it is not currently covered by private insurance or Medicare. OPKO Laboratory cites a $395 current cost to patients for the test.
PHI
The PHI blood test (Beckman Coulter, Brea, CA, USA) combines PSA, free PSA and p2PSA through the formula: phi = (p2PSA/fPSA) 9 √(tPSA). It predicts the likelihood of finding prostate cancer on a subsequent biopsy.
The basis of the PHI lies in the identification of the free PSA precursor isoform [-2]proPSA, which forms 25-95% of the fPSA fraction in men with prostate cancer, compared with just 6-19% in biopsy-negative men. 4 In a number of studies comparing total PSA with the calculated PHI, higher PHI values were associated with a higher percentage of positive biopsies, as well as with a higher percentage of high-grade cancer (Gleason score of ≥7).
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In a study involving serum samples of 405 men from the Rotterdam arm of the European Randomized Study of Screening for Prostate Cancer and 351 men from an independent site, the PHI provided an AUC as high as 0.750 for detecting prostate cancer, as compared with just 0.585 for the serum PSA test. 6 This was further validated in a multicenter European trial by Lughezzani et al. involving 883 patients, which showed that an AUC of 0.68 (95% CI 0.64-0.72) predicted prostate cancer at biopsy (Table S2) . 8 The PHI's main limitation is that it is designed to predict the likelihood of finding any prostate cancer on repeat biopsy, regardless of the Gleason score. The PHI does not stratify by risk, and its use, therefore, can ideally be in conjunction with other clinical parameters or a nomogram.
PHI has been cleared by the FDA for use in men aged >50 years who have a PSA level between 4 and 10 ng/mL, and DRE findings that are not suggestive of cancer. The test is relatively inexpensive (approximately $80-100), and is covered by Medicare and most other insurance carriers.
PCA3/Progensa
PCA3 was first described in 1999. 9 A non-coding prostatespecific mRNA, PCA3 is overexpressed in prostate cancer tissue, as compared with benign prostate tissue. The PCA3 assay is a PCR nucleic acid amplification test that measures the ratio of the concentration of PCA3 to PSA mRNA in post-DRE first-catch urine specimens.
A PCA3 score of <25 is considered "negative," and is associated with a <15% likelihood of a positive biopsy result. A score of ≥25 is considered "positive," and is associated with a >25% likelihood of a positive biopsy result. A previously established cut-off of 35 had been used in many studies, which found the positive biopsy rate to be 39% and the missed detection rate to be 22%. 10 However, the FDA approval for the test included a requirement for a lower cutoff to enhance sensitivity. A cut-off of 25 found the test's reported sensitivity for predicting cancer on the next biopsy to be 77.5% and its specificity 57.1%. Marks et al. studied the PCA3 assay in 233 men with a PSA level of ≥2.5 ng/mL and at least one prior negative prostate biopsy. 11 An AUC of 0.678 was shown for the PCA3 score, as compared with just 0.524 for serum PSA levels. Risk of a positive biopsy increased with increasing PCA3. In the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, a subset of 1140 patients provided urine samples for PCA3 analysis. 12 Patients with positive biopsies had a median PCA3 score of 33.8, as compared with 16.7 for those with negative biopsies. This study reported an AUC of 0.693 (95% CI 0.649-0.736) for PCA3, as compared with 0.612 for serum PSA (95% CI 0.570-0.655; Table S3 ).
The PCA3 test has also been used in conjunction with TMPRSS2:ERG and other genetic data to aid in biopsy decisions (see Advanced Disease Prognosis and Treatment Response).
The Progensa PCA3 assay (Hologic, Bedford, MA, USA) is FDA-cleared for use in men aged ≥50 years who have had one or more previous negative prostate biopsies, and for whom a repeat biopsy would otherwise be recommended. The list price ($385) is covered by most insurance providers including Medicare.
ConfirmMDx
The ConfirmMDx (MDxHealth, Irvine, CA, USA) test is an epigenetic assay (i.e. it examines changes to DNA other than sequence changes). It quantifies DNA hypermethylation of three genes associated with prostate cancer. Methylation of those three genes is believed to occur even in non-malignant cells that are contiguous with cancer tissue, leading to a field effect. Taking advantage of this, the test is carried out on a patient's previous "negative" prostate biopsy specimens.
GSTP1 (involved in DNA detoxification), APC (involved in apoptosis) and RASSF1 (involved in cell cycle regulation) are frequently found to have hypermethylated CpG islands in their promoter regions in the context of cancer. These changes are believed to occur early in cancer development, and can be measured using a methylation-specific PCR assay. Stewart et al. retrospectively assessed 423 patients who had two consecutive negative biopsies followed by either a positive or negative repeat biopsy. 13 In those patients, DNA methylation of the three genes was an independent predictor for identifying who would have cancer detected on repeat biopsy (OR 3.17, 95% CI 1.81-5.53, P < 0.0001). The sensitivity was 68%, specificity 64% and negative predictive value 90% (Table S4) .
ConfirmMDx is priced at $3300. Limited Medicare coverage (up to approximately $2000) is available, as part of MDxHealth's ongoing randomized clinical utility study called PASCUAL. To qualify for coverage, patients must be aged between 40 and 85 years, with at least one negative biopsy in the past 2 years and with consistently elevated cancer risk factors. The test is CLIA-certified.
Staging and primary treatment selection
Tests in this category are most useful in men who already have a diagnosis of prostate cancer, the aggressiveness of which is in question. The most common use of these tests is in appropriately selecting men for active surveillance.
Prolaris
The Prolaris test (Myriad Genetics, Salt Lake City, UT, USA) reports a score derived from the mRNA expression levels of 31 CCP genes. The expression pattern of CCP genes is thought to indirectly measure the growth rate and the potential aggressiveness of tumor cells. This test is used to identify men who might harbor more aggressive disease than clinical features alone suggest. It has been studied in biopsy, radical prostatectomy specimens and after definitive radiation therapy. From biopsy specimens, the test output is a CCP score that predicts the percentage likelihood of biochemical recurrence (data censored at 10 years) in men if they were to undergo radical prostatectomy, and when combined with other clinicopathological data in the Cancer of the Prostate Risk Assessment (CAPRA score, which includes PSA, Gleason score, clinical stage, percentage of positive biopsy cores and age), the 10-year prostate cancer-specific mortality risk in prostatectomy specimens, the CCP score predicts the 10-year cancer-specific mortality when the sample is derived from the index tumor (defined as the largest highestgrade tumor in the specimen). 14 Cuzick et al. examined 31 CCP genes in a retrospective study group that included men who had undergone radical prostatectomy and men who had prostate cancer diagnosed through transurethral resection of the prostate chips. 15 Among the prostatectomy patients, a high CCP score was predictive of biochemical recurrence (increase in HR of 1.89 for a 1-unit change in CCP), with only weak correlation with the Gleason score and PSA level. In the transurethral resection of the prostate patients, the prognostic value of CCP gene expression was similar, although the risk score in this cohort included the PSA level and Gleason score as part of the calculation. Cuzick et al. further validated the CCP score in two cohorts of needle biopsy patients, showing the ability of the CCP when combined with information in the CAPRA score to predict the 10-year prostate cancer specific mortality risk. 15 Furthermore, one small retrospective study by Freedland et al. showed that the CCP score could be used to predict biochemical recurrence, and was associated with 10-year prostate cancer-specific mortality after definitive radiation therapy (Table S5) . 16 Prolaris is cleared by the FDA for use in men with NCCN-defined low-risk prostate cancer, and for post-prostatectomy patients who are at high risk for prostate cancer recurrence. It has also been incorporated as an option in the NCCN and European Association of Urology guidelines for prostate cancer. The list cost for the Prolaris test is $3400. Myriad Genetics provides payment plan options if out-ofpocket expenses for a patient exceed $375.
Oncotype DX Prostate
The Oncotype DX prostate assay (Genomic Health, Redwood City, CA, USA) is a RT-PCR-based gene expression assay that assesses the expression of 17 genes (12 cancer-related genes, 5 reference genes) involved in four metabolic pathways, including androgen signaling, cellular organization, stromal response and cellular proliferation. Based on expression levels, a GPS is reported, ranging from 0 to 100. Assays are run on cancer tissue from prostate needle biopsies in men with a Gleason score of 3 + 3 or low volume Gleason 3 + 4. The assay predicts the likelihood of unfavorable pathology, defined by the presence of a dominant Gleason pattern 4, or any Gleason pattern 5, extracapsular extension, seminal vesical invasion or positive surgical margins after radical prostatectomy. The test is mainly used to help select patients for active surveillance.
Klein et al. carried out a validation study involving 395 patients who underwent a radical prostatectomy with a Gleason score of 3 + 3 (76%) or low-volume Gleason 3 + 4 disease (24%). 17 A multinomial regression analysis controlled for the Gleason score. The GPS was a statistically significant predictor of pathological outcome (P = 0.002). Each 20-point increase in the GPS predicted an approximately twofold increase in the risk of adverse pathology (OR 1.85, 95% CI 1.23-2.81, P < 0.003).
Another validation study used biopsy tissue from a more diverse cohort, including 82 African Americans (20% of the cohort). It identified a similar ability of GPS to predict time to biochemical recurrence and adverse pathology. Furthermore, the GPS results were similarly distributed in black and white men, with a median GPS of approximately 30 for both (Table S6) . 18 The test costs $4180. It is covered by Medicare for men with NCCN-defined low-and very-low-risk prostate cancer, and has also been incorporated into the NCCN prostate cancer guidelines. Genomic Health notes that for other carriers, financial assistance will be provided to patients if out-ofpocket costs exceed $100.
Post-treatment risk stratification
This category of tests can be used to determine which men have the highest risk of cancer recurrence after definitive therapy, and to predict disease progression in men with advanced disease.
Decipher
The Decipher test (GenomeDx Biosciences, San Diego, CA, USA) uses a gene-expression panel on post-prostatectomy tissue samples to determine a GC risk score. The GC risk score assesses 22 genes involved in cell proliferation, migration, tumor motility, androgen signaling and immune system evasion. It predicts the likelihood of clinical disease recurrence at 5 years after prostatectomy in men with adverse pathological features (e.g. extracapsular extension, seminal vesicle invasion, positive surgical margins) on final post-prostatectomy pathology.
Key genes were identified in 2008 by Nakagawa et al., who studied 570 genes implicated in prostate cancer progression in a group of 623 men who had undergone a prostatectomy. 19 Decipher has also been studied specifically in African Americans to identify differential gene expression signatures in post-prostatectomy tissue. 20 A total of six genes were found to have significantly different expression in black patients, perhaps partially providing insight into genetic and biological explanations for outcome disparities.
Den et al. examined the use of the GC risk score to guide radiation therapy after radical prostatectomy. 21 In patients with pT3 or margin-positive prostate cancer, the cumulative incidence of metastasis at 5 years after radiation therapy was 0%, 9%, and 29% for low, average and high GC risk scores, respectively. In the group with low GC risk scores, a multivariable analysis found no difference in the cumulative incidence of metastasis at 5 years in patients who underwent adjuvant versus salvage radiation; however, in the group with average and high GC risk scores, the incidence was 6% in patients who underwent adjuvant radiation versus 23% in those who underwent salvage radiation (P < 0.01). That difference translated to an 80% risk reduction (HR 0.20) in patients with high GC risk scores who underwent adjuvant (vs salvage) radiation. More recently, Klein et al. reported an initial validation study showing the use of Decipher in the biopsy setting. 22 When combined with NCCN risk stratification, a 10% increase in the GC risk score was associated with an HR increase of 1.72, for the risk of metastasis within 10 years of prostatectomy. The study analyzed needle biopsy tissue from 57 men who underwent radical prostatectomy (median follow up 8 years). A high GC risk score was also a significant predictor of primary cancer with a Gleason score of 4 or more (Table S7) . 22 Decipher costs approximately $4250. It is covered for Medicare patients to enhance risk stratification. It is also covered to measure metastatic risk in Medicare patients who have pT2 margin-positive prostate cancer, pT3 prostate cancer or a rising PSA level after an initial nadir. The test is CLIA-certified.
Advanced disease
Tests in this category can be used to monitor disease progression or treatment response in men with advanced disease.
CTCs
Measurement of CTCs (CellSearch CTC test; Janssen Diagnostics BVBA, Mechlen, Belgium) in peripheral blood is emerging as a marker of cancer progression. CTC are believed to mediate the hematogenous spread of cancer to distant sites. The CellSearch CTC test identifies epithelial cell-specific adhesion markers to distinguish CTCs from normal blood cells. No consensus has been reached on which particular CTC level is a cut-off for "good" or "poor" prostate cancer, although a level of five CTCs/7.5 mL is often used. In 231 patients with castration-resistant disease, de Bono et al. found that certain CTC levels were predictive of overall survival -and more accurately and independently than standard PSA levels. 23 Patients with five or more CTCs/ 7.5 mL had a median overall survival time of 11.5 months; in contrast, those with more than five CTCs/7.5 mL had a median overall survival time of 21.7 months.
Goldkorn et al. reported a prospective validation study of CTCs as a marker for prognosis in men receiving docetaxel therapy. 24 A change in CTC levels at day 21 (after 1 cycle of chemotherapy) was prognostic of overall survival, suggesting that CTC measurement can serve as a metric to guide early therapy redirection.
Currently, the widespread use of CTC detection kits is limited because of the lack of specificity of epithelial cell-specific adhesion markers, as well as inadequacies in cell recovery, in sampling accuracy and in analytic methods. The identification of circulating (cell-free) nucleic acids has also emerged as a diagnostic marker for circulating tumor cells. 25 A small amount of tumor DNA is believed to be released into plasma circulation in the form of cell-free DNA. Preliminary efforts have shown the detection of androgen receptor mutations in cell-free DNA isolated from patients with castrationresistant prostate cancer. 26 Antonarakis et al. described the use of quantitative RT-PCR to prospectively identify AR-V7 within the CTCs of men taking either enzalutamide or abiraterone. 27 In 62 of these men with metastatic castration-resistant prostate cancer, those with AR-V7-positive cancer had lower PSA response rates than those with AR-V7-negative cancer. Although yet to be validated in a larger cohort, those results provide yet another approach to CTC measurement and analysis, potentially enabling early identification of responders to novel therapeutic agents (Table S8) .
TMPRSS2:ERG
This is an abnormal chromosomal rearrangement that results in overexpression of the transcription factor ERG, which inhibits normal prostate differentiation. 28 In prostate cancer, gene expression analyses have identified high levels of ERG (21q22.3) and ETV1 (7p21.2) -two genes that encode ETS family transcription factors that have been previously linked to leukemia and to Ewing's sarcoma. In 2005, Tomlins et al. reported fusion of ERG or ETV1 to TMPRSS2, a gene expressed in the normal prostate and strongly induced by androgens, in the LNCaP prostate cancer cell line and in cell lines derived from patients with metastatic prostate cancer. 29 In their microarray analysis, ERG and ETV1 were markedly overexpressed in close to 60% of prostate cancer tissue samples, but in no benign samples. In >90% of the samples that overexpressed ERG or ETV1, fusion with TMPRSS2 was found, suggesting fusion as the most likely cause of overexpression. In men who underwent a radical prostatectomy, Leyten et al. observed that TMPRSS2:ERG expression was an independent predictor of extracapsular extension (OR 4.98; P = 0.034). 30 According to a validation cohort of more than 1100 patients at the University of Michigan, the detection of TMPRSS2:ERG in post-DRE urine samples, when combined with PCA3 expression and PSA levels, had an AUC of 0.751 for detecting prostate cancer on biopsies, as compared with an AUC of 0.585 for PSA levels alone. 31 This commercially available combined test platform is now called the Michigan Prostate Score. For the detection of high-grade cancer (defined per the Michigan Prostate Score as a Gleason score >6), the PSA-TMPRSS2:ERG-PCA3 model showed an AUC of 0.772. This indicates that at certain thresholds, use of these tests in combination can reduce unnecessary biopsies (Table S9 ). An exosome urine assay that includes TMPRSS2: ERG and PCA3 has also been reported (see Emerging Tests below).
Given the heterogeneity of studies reporting conflicting prognostic values of the test, the true utility of TMPRS22: ERG measurement is still unknown.
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Emerging tests
ExoDx Prostate IntelliScore
The ExoDx Prostate IntelliScore assay (Exosome Diagnostics, Cambridge, MA, USA) is a first-catch urine test that assesses the RNA levels of PCA3, TMPRSS2:ERG and SAM pointed domain-containing Ets transcription factor. It varies from other tests that detect PCA3 and TMPRSS2:ERG in its ability to purify RNA from exosomes, which are secreted from cell membranes, and encapsulate both proteins and mRNA. Before urine collection, a DRE is not required. The RNA cycle threshold values of PCA3, TMPRSS2:ERG and SAM pointed domain-containing Ets transcription factor were used to determine a gene expression assay score. A study utilizing a training and validation cohort of 774 patients found that the gene signature had an AUC of 0.74 (95% CI 0.68-0.80) for predicting high-grade cancer, as compared with an AUC of 0.61 (95% CI 0.54-0.69) for PSA. 32 With a score cut-off set to provide a sensitivity of 92%, the assay missed just 12 of 148 high-grade cancers. The test is not yet FDA-cleared.
Prostarix
This post-DRE urine test (Metabolon, Durham, NC, USA) measures four metabolites: sarcosine, glycine, alanine and glutamate. The quantitative values of those metabolites are then used in a proprietary algorithm to generate a risk score, ranging from 0 to 100. The risk score predicts the likelihood of cancer on a prostate biopsy; that is, a score of 40 translates to a 40% likelihood of a positive biopsy result. The test is indicated for men who have or have not had a previous biopsy.
The primary metabolite of interest is sarcosine, which is generated from the methylation of glycine by glycine Nmethyltransferase. Cellular invasiveness (a measure of aggressiveness) was noted to correlate with increased glycine by glycine N-methyltransferase overexpression. 33 An in vitro immunohistochemistry and quantitative PCR study of 652 urine specimens determined metabolite cut-offs. To date, the test has not been prospectively evaluated (Table S10) . 34 The test is not FDA-cleared. No information on cost is available.
Prostate Core Mitomic Test
Using RT-PCR, this genomic assay (MDNA Life Sciences, Broomfield, CO, USA) quantifies a 3.4-kb mitochondrial DNA deletion that has a highly significant association with prostate cancer. Like the ConfirmMDx test, it evaluates previous negative prostate biopsy specimens to draw conclusions about a field effect in cells that might be contiguous with prostate cancer lesions. Maki et al. compared biopsy specimens of tissue adjacent to known malignant needle cores with benign and positive specimens, using quantitative PCR to assess mitochondrial DNA. 35 Specimens of malignant and histologically normal biopsy specimens from areas adjacent to malignant tissue had similar mitochondrial DNA scores, which varied significantly from the scores of distant benign tissue (Table S11 ). The test is not currently FDAcleared.
Discussion
The rapid and continually evolving realm of prostate cancer biomarkers poses both new opportunities and challenges to practicing physicians. When used appropriately, these tests can provide guidance in selecting patients for biopsy and minimizing overdiagnosis. They can also help identify patients with higher-risk disease who might benefit from more aggressive management. Challenges remain, however, in determining which tests to rely on, particularly when results appear to be incongruent with other clinical data. Physicians must therefore carefully familiarize themselves with the indications of each test, the study populations for which the tests have been validated and the clinical implications of each test's results.
Our own experience has allowed us to develop an algorithm to guide test selection (Fig. 1) . Patients who are uncertain about whether they should proceed with a biopsy after PSA screening, or those who have had prior negative biopsies with a rising or persistently elevated PSA, might benefit from testing with the 4Kscore, PHI, ConfirmMDx or PCA3/combination TMPRSS2:ERG tests. These tests provide information that predict the likelihood of finding cancer, or clinically significant cancer on a biopsy, which can help guide counseling. We have found over time that the PCA3 test has lower utility with the same or higher cost compared with other tests, and hence tend to use it less. In contrast, patients who have low-volume Gleason 6 disease on an initial biopsy who are uncertain about active surveillance might benefit from an OncotypeDX or Prolaris assay to better ascertain the aggressiveness of their disease. For individuals who have undergone a prostatectomy and who have either a positive surgical margin or pT3 disease, the question of timing of adjuvant/salvage radiation therapy is a source of anxiety and debate. The Decipher test can be used in this setting to identify individual metastatic risks, and in turn direct this decision.
An important finding of the present review was that black people remain underrepresented in most validation studies to date -despite the fact that they have a higher incidence of prostate cancer and death rates more than 2.4-fold higher 36 It is unclear how most of these tests perform in black patients, and this limitation should be discussed.
Another unresolved issue is how initial test results can change with repeat assessments. This is particularly relevant for the genomic markers, as gene expression changes can occur over time. As prostate cancer as a disease evolves in an individual, an assessment using one of these tests only represents a snapshot of the disease state at the time tested. Static assessments of the biological status of the prostate gland at a single point in time is unlikely to be adequate in terms of disease behavior 1 or more years later. Further research into how the information from these tests changes with repeat measurements is required.
Cost is another important issue. Several of the tests are covered by insurance programs, but many are not. For patients with no or inadequate insurance, financial support to limit out-of-pocket costs is provided by many vendors; however, many of these financial support programs exist for purposes of test introduction, so support might not be available in the future. In this era of growing cost-consciousness, physicians must be increasingly aware of the additional expenses that these tests contribute to prostate cancer care. Research in this area is ongoing. Clearly, these tests should be used with discretion.
Conclusion
Integration of genomic and molecular tests that use novel biomarkers offer both new opportunities and challenges in prostate cancer management. The first step in their use is to understand their indications and limitations. They should not replace standard clinical information and physician judgment, but they might serve as an important adjunct to existing management tools. Clinicians should carefully evaluate each novel biomarker and discuss their use in appropriately selected patients.
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